Investigator-Initiated Trials (IIT) in China: Why Dealmakers Care, and Whether the Data Travels (2026)
China runs the overwhelming majority of its early cell-therapy studies as IITs — fast, cheap human proof-of-concept that de-risks an asset years before a registration trial. The question every cross-border dealmaker must answer: does that data actually travel?
Why This Matters
China's investigator-initiated trial track is the hidden engine behind much of the country's cell-therapy and oncology pipeline — and behind a record ~$136B of out-licensing value flowing to Western partners. Get the IIT question right and you can in-license a clinically validated asset years ahead of the field; get it wrong and you pay a premium for data that an FDA reviewer will never accept. This guide separates the proof-of-concept value of an IIT from its regulatory weight — the distinction on which a deal is won or lost.
What an IIT Is — and China's Dual-Track System
An investigator-initiated trial (IIT) in China is a clinical study sponsored and conducted by a qualified investigator and their medical institution rather than by a drug company seeking a marketing licence. The hospital is the sponsor; the principal investigator owns the protocol; and the regulator of record is the National Health Commission (NHC), not the drug regulator. This is the defining feature of China's "dual-track" system, which has governed advanced therapies since around 2017 and was formalized nationally in 2025.
The two tracks answer two different questions. The NMPA/CDE trackasks "can this product be sold?" and demands a formal Investigational New Drug (IND) dossier, CDE technical review, full ICH-GCP conduct, and ultimately a Biologics License Application (BLA) or New Drug Application (NDA). The NHC trackasks "is this technology worth pursuing?" and treats the intervention as a medical technology explored inside an accredited hospital — requiring institutional academic and ethics-committee review and China GCP, but no CDE clearance and no commercial dossier. A useful mental model: the IND track is the regulated highway to market; the IIT track is the hospital laboratory where the asset first meets a human being.
Three approval layers still apply to most IITs and matter enormously in diligence. First, institutional ethics committee approval at the hospital. Second, compliance with China GCP (now ICH-aligned since China joined the ICH in 2017). Third — and frequently overlooked by foreign buyers — Human Genetic Resources (HGR) approval. Under the Administrative Regulations on Human Genetic Resources (revised 2024, effective 1 May 2024, with oversight transferred from the Ministry of Science and Technology to the NHC), foreign parties cannot collect, store, or export Chinese human genetic material or related data without a Chinese partner and, in defined cases — such as important genetic families, specific regions, or large-scale population studies above the regulatory case threshold — explicit government approval. An IIT that generated samples or data without clean HGRAC clearance is a latent liability in any cross-border deal.
| Dimension | IIT (NHC track) | Registration / IND trial (NMPA track) |
|---|---|---|
| Sponsor | Hospital / investigator (often with corporate funding) | Pharmaceutical or biotech company |
| Regulator | National Health Commission (NHC) | NMPA / Center for Drug Evaluation (CDE) |
| Pre-trial clearance | Institutional academic + ethics review; NHC filing | Formal IND dossier and CDE clearance |
| Primary purpose | Scientific exploration, early proof-of-concept | Support a marketing application (BLA/NDA) |
| Typical speed to first patient | Fast — no CDE cycle, no pre-IND meeting, no dossier translation | Slower — historically months; now ~30 working days under the new pathway |
| Regulatory weight of data | Supportive / hypothesis-generating | Pivotal — designed for registration |
| FDA acceptability (standalone) | Generally not accepted on its own | Acceptable within a properly designed MRCT |
Why IITs Dominate China Oncology and Cell Therapy
IITs matter because they manufacture human proof-of-concept faster and cheaper than any company-sponsored route on earth — and in China's hottest modalities, that is decisive. In cell and gene therapy the dominance is not subtle. A 2025 review in Clinical and Translational Science (Yang et al.) found that, as of 1 August 2024, IITs accounted for roughly 90% of registered Chinese cell-therapy studies— about 2,519 of some 2,800 trials — with company-sponsored IND studies a small minority. China's cell-therapy pipeline is now the second-largest in the world behind the United States, and the IIT track is the soil it grew in.
The logic is straightforward. CAR-T and other autologous cell products are bespoke and capital-intensive; running a full IND-enabling CMC and nonclinical package before you know whether the construct even works in humans is an expensive bet. An IIT lets a Chinese academic group — often in partnership with a young biotech — dose a handful of relapsed/refractory patients at a leading hospital and read out an objective response rate within months. If the signal is strong, the asset is suddenly de-risked and financeable; if it is weak, the team has spent a fraction of what a formal program would have cost. The IQVIA Asia-Pacific team frames IITs precisely this way: a tool for dose exploration, indication expansion, and de-risking larger regulatory investment — a complementary first step to an IND, not a replacement for it.
The canonical example is Legend Biotech's LCAR-B38M. Its first-in-human evidence came from the investigator-initiated LEGEND-2study (NCT03090659), run across four hospital sites in China — anchored at the Second Affiliated Hospital of Xi'an Jiaotong University under PIs Wang-Gang Zhang and Ai-Li He — reporting deep, durable responses in relapsed/refractory multiple myeloma. That CAR construct is identical to ciltacabtagene autoleucel (cilta-cel), later partnered with Johnson & Johnson's Janssen and approved globally as Carvykti. A second example is CARsgen's CT053 (zevor-cel), a fully-human anti-BCMA CAR-T first studied in investigator-initiated Phase 1 work in eastern China and subsequently approved by the NMPA. In both cases the IIT was the ignition event — the first human data that turned a construct into a clinical and commercial asset.
The flywheel IITs created
The Dealmaker Question: Does IIT Data Travel?
The short answer: IIT data powerfully informs a deal but generally does not, by itself, support a US regulatory filing. This is the single most important distinction in the entire topic, and it is where inexperienced buyers overpay. The FDA's rule for foreign studies not run under a US IND is 21 CFR 312.120: such data can support an IND, NDA, or BLA only if the study was conducted in accordance with GCP — including review by an independent ethics committee and documented informed consent — and the FDA is able to validate the data, in practice through the ability to conduct an onsite inspection of source records. Most IITs were never built to that bar. Their protocols, monitoring, source-data trails, and consent documentation are designed for academic publication and internal go/no-go, not for an FDA inspector reconstructing every data point.
There is a second, distinct barrier that applies even to clean data: applicability and diversity. The FDA has repeatedly declined to approve drugs on the basis of single-country Chinese datasets, arguing the population and standard of care may not represent US practice. The expected solution is the multi-regional clinical trial (MRCT) under ICH E17, with Chinese and ex-China sites and a pre-specified plan for regional subgroups. A systematic review of international oncology approvals across the US, EU, Japan, and China found that the large majority of recent cancer drugs reached market on the strength of MRCTs rather than single-country trials — underlining that geography of evidence, not just its quality, drives acceptance. An IIT is, by definition, neither multi-regional nor designed for registration.
So how should a buyer treat it? As a high-value go/no-go signal and a head start, not as a finished dataset. In practice, well-structured cross-border deals now carry "technical data sharing" clausesthat let the Western partner mine the Chinese Phase 1/IIT data to design and accelerate its own US IND — using the China evidence to pick the dose, define the population, and frame regulatory interactions, while still running a fresh, GCP-compliant confirmatory program. The IIT shortens the path; it does not remove the registration trial. Note the policy risk on the horizon: report language in the US House Agriculture–FDA appropriations process has sought to bar the FDA from accepting clinical data generated at sites in China — and certain other countries such as Russia, Iran, and North Korea — in support of IND applications. The provision's fate is uncertain, but it sharpens the case for designing assets that can re-generate pivotal data outside China if required.
The overpayment trap
The 2025–26 Reform Context: Order 818 and the 30-Day IND
Two 2025 reforms reshaped the IIT calculus — one formalizing the IIT track itself, the other making the IND track dramatically faster. First, State Council Order No. 818 — the Regulations on the Administration of Clinical Study and Clinical Translation and Application of New Biomedical Technologies — was issued on 10 October 2025 and takes effect on 1 May 2026. For the first time, China has a national framework for IITs in cell therapy, gene therapy, gene editing, stem cells, and tissue engineering. The previous patchwork — hospital-by- hospital oversight with inconsistent rigor — is replaced by a filing-based system in which only the highest-tier Grade A tertiary hospitals may host these studies, and approved studies must be filed with the NHC within five working days of academic and ethics review.
The structurally significant change in Order 818 is who may sponsor. Initiation is no longer limited to medical institutions: biopharmaceutical companies — including foreign companies that establish a registered China presence through a subsidiary or local joint venture — can now initiate these clinical studies. That converts the IIT track from a purely academic on-ramp into a deliberate corporate development tool, and it opens a compliant route for Western players to participate in China's cell-therapy proof-of-concept engine rather than merely buy its outputs after the fact.
Second, NMPA Announcement [2025] No. 86 — issued in October 2025 to roll out a 2024 pilot nationwide — created a 30-working-day IND review pathway for eligible Class 1 innovative drugs (chemicals, biologics, and traditional Chinese medicines), including globally synchronized Phase 1/2 programs and certain investigator-led MRCTs. The CDE issues an acceptance decision within 5 working days, the substantive review targets 30 working days (extendable to 60 for complex cases), and applicants must commit to dosing the first Chinese subject within 12 weeks of clearance. When the formal IND route compresses to roughly a month, part of the historical speed advantage of jumping straight to an IIT narrows — a shift dealmakers should factor into asset timelines. For the full registration mechanics, see our NMPA drug-approval process guide.
| Reform | What it does | Key dates | Why dealmakers care |
|---|---|---|---|
| Order No. 818 | National IIT framework for advanced therapies; companies (incl. foreign) may sponsor; Grade A tertiary hospitals only; 5-working-day NHC filing | Issued 10 Oct 2025; in force 1 May 2026 | A compliant route to initiate or co-own IIT proof-of-concept, not just buy it later |
| NMPA Announcement [2025] No. 86 | 30-working-day IND review for eligible Class 1 innovative drugs; 5-day acceptance; 60-day fallback; first dose within 12 weeks | Issued Oct 2025 (nationwide rollout of 2024 pilot) | Narrows the IIT speed edge; makes the registration path itself a viable fast option |
| HGR Regulations (revised) | Foreign use of Chinese genetic material/data requires a Chinese partner and, in defined cases, government approval; oversight now under NHC | Effective 1 May 2024 | A diligence gating item — unclean HGRAC status is a latent deal liability |
The BD Payoff: IIT Proof-of-Concept as a Valuation Lever
The commercial reason IITs matter is timing: an early human signal lets you transact before the rest of the market reprices the asset. China-origin out-licensing reached a record in 2025 — roughly $135.7B in announced deal value, on the order of a third of all global licensing spend — and, crucially, nearly three-quarters of those pacts involved preclinical or Phase 1 assets. Early-stage deals depend on early-stage evidence, and in cell therapy and oncology that evidence is very often an IIT readout. The IIT is what makes a still-cheap asset credible enough to license.
For an out-licensor, the strategic move is to use the IIT to cross the proof-of-concept inflection, then take the asset to market while the data is fresh and before a formal registration trial both consumes capital and tips competitors off. For an in-licensor, the move is the mirror image: find assets where a strong IIT signal has not yet been fully recognized, and structure a deal that pays modest upfront with milestones loaded onto IND clearance, confirmatory data, and approval. Reflecting exactly this risk profile, a typical billion-dollar-plus China deal in 2026 might carry only $50–80M upfront, with the bulk of value tied to back-end triggers such as US IND clearance, NMPA approval, and commercial sales tiers. The IIT sets the entry price; the milestone structure prices the regulatory risk that the IIT cannot retire on its own.
Sourcing these assets at the IIT stage requires a network that reads hospital-led data in real time and relationships with the academic groups and young biotechs running it. Vision Lifesciences operates as one of the leading cross-border China–West advisory firms, with senior teams in Hong Kong, Shanghai, Zurich, and Chicago and one of the deepest China–West deal networks in the sector. That reach is what lets a buyer identify an IIT-validated asset before the registration trial reprices it — and helps an out-licensor convert an IIT signal into the best available terms. For the broader scouting and structuring playbook, see our guide to in-licensing biotech assets from China and our out-licensing advisory.
How to Diligence an IIT-Backed Asset
Diligence on an IIT-backed asset is fundamentally a verification and re-generation exercise: confirm the signal is real, confirm it is clean, and confirm you can rebuild it to a registration standard. The strength of an IIT readout is not a substitute for asking whether that readout would survive scrutiny. Five questions separate a real opportunity from an expensive mirage.
1. Is the data integrity inspection-grade? Obtain the actual IIT protocol, amendments, monitoring records, and a sample of source documents. Reconcile reported response rates against source data and confirm follow-up duration is long enough to support the efficacy claim. Ask directly: would this survive an FDA bioresearch monitoring inspection? If not, model the cost and time to re-generate it. 2. Is informed consent and ethics documentation complete? Confirm ethics-committee approvals exist for every site and that consent forms cover downstream commercial use and data transfer — gaps here can invalidate the data for any Western filing.
3. Is the HGRAC and data-export position clean? Verify that any genetic material and data were collected and any cross-border transfer was made in compliance with the Human Genetic Resources rules — a frequent and underestimated source of deal risk. 4. Who owns the construct and the data? In IITs run with academic hospitals, intellectual property and data rights can be entangled between the institution, the investigator, and the funding company; confirm clean, transferable title before pricing the deal. 5. What is the realistic registration plan? Map the path to a GCP-compliant, MRCT-style program that the FDA and NMPA will accept, treating the IIT as supportive evidence only, and price milestones against that plan. Choosing the right CRO and site network to execute that confirmatory program is its own decision — our China CRO landscape guide and analysis of China's clinical-trial cost and speed advantages cover the operational side, and the China biotech ecosystem guide maps where these assets originate.
The diligence reframe
Conclusion
Investigator-initiated trials are the proof-of-concept engine of China's cell-therapy and oncology innovation — responsible for roughly 90% of early cell-therapy studies and for the first human data behind landmark assets from Legend's cilta-cel to CARsgen's zevor-cel. For a cross-border dealmaker their value is real but specific: an IIT delivers a fast, cheap, de-risking signal that lets you transact early and at the right price. What it does not deliver is registration-grade evidence — IIT data generally cannot, on its own, support an FDA IND or BLA, and single-country Chinese data demands an MRCT to travel at all. The 2025–26 reforms — Order No. 818 formalizing the IIT track and opening it to companies, and NMPA Announcement [2025] No. 86 compressing IND review to 30 working days — make this landscape both more accessible and faster-moving. The winning approach is disciplined: prize the IIT for the signal it gives, verify it ruthlessly, and price the deal against the confirmatory data that actually carries regulatory weight.
Evaluating an IIT-backed China asset?
Vision Lifesciences advises buyers and sellers on cross-border China–West biotech transactions — from sourcing IIT-validated assets to verifying the data and structuring deals that price regulatory risk correctly. Talk to our clinical, regulatory, and deal teams in Hong Kong, Shanghai, Zurich, and Chicago.
Speak with our advisory teamLearn more about Vision Lifesciences and our cross-border advisory practice.